Physician profile

Eleni Anastasia Tousimis

Surgery · Miami, FL

NPI 1609972033

$33,351.98

in general payments reported to CMS, 2019-2025

3 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$5,312.50
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$3,084.50
Travel and Lodging$2,067.13
Food and Beverage$286.82

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic USA, INC. $14,111.93 2019
Medtronic, INC. $12,033.96 2022-2023 Plasmablade(Tm)
Axogen $7,206.09 2023-2024 Axoguard Nerve Protector, Axoguard Nerve Connector, Avance Nerve Graft

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eleni Anastasia Tousimis

$33,351.98

in general payments reported 2019-2025

Years
2019-2024
Top company
Medtronic USA, INC.

https://glasscript.com/doctor/118890/eleni-anastasia-tousimis

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.